{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T00:46:18Z","timestamp":1794357978647,"version":"4.9.0"},"reference-count":118,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000774","name":"Defense Threat Reduction Agency","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Ebola virus (EBOV) is the causative agent of Ebola disease (EBOD), a viral hemorrhagic fever with a notably high case fatality rate. Current treatments for EBOD are limited to monoclonal antibodies or two licensed viral vector vaccines, a recombinant vesicular stomatitis virus (rVSV)-vectored vaccine or an adenovirus and modified vaccinia Ankara regimen. However, comparisons of protection, efficacy, and durability with alternative nucleotide platforms remain understudied. Here, we evaluated the immunogenicity of an mRNA vaccine expressing the EBOV glycoprotein (GP) in parallel with rVSV- and DNA-based vaccine platforms. The mRNA EBOV-GP vaccine, formulated in lipid nanoparticles, elicited significantly higher levels of total IgG and neutralizing antibody titers compared to the rVSV-EBOV-GP vaccine. Linear antibody epitope analysis indicated a preference for targeting the mucin-like domain in EBOV-GP1 following rVSV-based vaccination, while the mRNA platform distinctly targeted the internal fusion loop of EBOV-GP2. After characterizing the immunogenicity of the mRNA vaccine, two models of EBOD were used to demonstrate its protective efficacy: a surrogate rVSV-based challenge model of EBOD using type-I interferon deficient C57BL\/6 mice and infection of BALB\/c mice with authentic mouse-adapted EBOV. In both studies, the EBOV mRNA vaccine fully protected the mouse cohorts against morbidity and mortality. Additionally, the EBOV mRNA vaccine produced greater neutralizing antibody titers compared to the DNA EBOV-GP vaccine. These results suggest that an mRNA vaccine expressing EBOV-GP can induce robust, functional humoral responses that are protective against EBOD, warranting further development as an alternative to, or as part of a vaccine strategy including, viral vectored vaccines.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1682418","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:37:55Z","timestamp":1767595075000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["An mRNA vaccine encoding the Ebola virus glycoprotein induces high neutralizing antibody titers and provides strong protection against lethal infections in mouse models"],"prefix":"10.3389","volume":"16","author":[{"given":"Zachary R.","family":"Stromberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvia E.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara C.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel F.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Altin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abisola","family":"Abisoye-Ogunniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Travis","family":"Gollott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris K. A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kwilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Mead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia A.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra K. G.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Schwedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb Z.","family":"Trecazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew W.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven B.","family":"Bradfute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas O.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay W.","family":"Hooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason T.","family":"Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Rasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar A.","family":"Negrete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.53854\/liim-3204-5","article-title":"Updated WHO list of emerging pathogens for a potential future pandemic: Implications for public health and global preparedness","volume":"32","author":"Ukoaka","year":"2024","journal-title":"Infez Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-019-0187-4","article-title":"New filovirus disease classification and nomenclature","volume":"17","author":"Kuhn","year":"2019","journal-title":"Nat Rev Microbiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jiph.2023.10.020","article-title":"Case fatality rate for Ebola disease, 1976\u20132022: A meta-analysis of global data","volume":"17","author":"Izudi","year":"2024","journal-title":"J Infection Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of Ebola virus disease*","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu Rev Pathology: Mech Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2017.11.006","article-title":"Viral hemorrhagic fever in the tropics: Report from the task force on tropical diseases by the World Federation of Societies of Intensive and Critical Care Medicine","volume":"42","author":"Hidalgo","year":"2017","journal-title":"J Crit Care"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-014-3515-1","article-title":"Understanding organ dysfunction in Ebola virus disease","volume":"40","author":"Fletcher","year":"2014","journal-title":"Intensive Care Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e0009300","DOI":"10.1371\/journal.pntd.0009300","article-title":"Early control of viral load by favipiravir promotes survival to Ebola virus challenge and prevents cytokine storm in non-human primates","volume":"15","author":"Reynard","year":"2021","journal-title":"PloS Negl Trop Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/v7020511","article-title":"Understanding Ebola virus transmission","volume":"7","author":"Judson","year":"2015","journal-title":"Viruses"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01888-22","article-title":"Characterization of Ebola virus mucosal challenge routes in cynomolgus macaques","volume":"97","author":"Johnson","year":"2023","journal-title":"J\u00a0Virol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1086\/520545","article-title":"Assessment of the risk of Ebola virus transmission from bodily fluids and fomites","volume":"196","author":"Bausch","year":"2007","journal-title":"J\u00a0Infect Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7316a1","article-title":"Use of Ebola vaccines\u2014worldwide, 2021\u20132023","volume":"73","author":"Kallay","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9030190","article-title":"Development of pandemic vaccines: ERVEBO case study","volume":"9","author":"Wolf","year":"2021","journal-title":"Vaccines"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7001a1","article-title":"Use of Ebola vaccine: recommendations of the advisory committee on immunization practices, United States, 2020","volume":"70","author":"Choi","year":"2021","journal-title":"MMWR Recommended Rep"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.78.10.5458-5465.2004","article-title":"Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of Filoviruses and Arenaviruses","volume":"78","author":"Garbutt","year":"2004","journal-title":"J Virol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/v8040113","article-title":"Validation of the Filovirus plaque assay for use in preclinical studies","volume":"8","author":"Shurtleff","year":"2016","journal-title":"Viruses"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e0274906","DOI":"10.1371\/journal.pone.0274906","article-title":"First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent Filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study","volume":"17","author":"Bockstal","year":"2022","journal-title":"PloS One"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12020210","article-title":"Long-term clinical safety of the ad26.ZEBOV and MVA-BN-filo Ebola vaccines: A prospective, multi-country, observational study","volume":"12","author":"Puri","year":"2024","journal-title":"Vaccines"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904387","article-title":"Ebola outbreak response in the DRC with rVSV-ZEBOV-GP ring vaccination","volume":"391","author":"Muyembe","year":"2024","journal-title":"New Engl J Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune responses to viral gene therapy vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2338","DOI":"10.1002\/rmv.2338","article-title":"Human adenovirus type 26 basic biology and its usage as vaccine vector","volume":"32","author":"Majhen","year":"2022","journal-title":"Rev Med Virol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.06.071","article-title":"Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk\/benefit assessment","volume":"34","author":"Clarke","year":"2016","journal-title":"Vaccine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105647","article-title":"Preclinical development of a replication-competent vesicular stomatitis virus-based Lassa virus vaccine candidate advanced into human clinical trials","volume":"114","author":"Cooper","year":"2025","journal-title":"eBioMedicine"},{"key":"B26","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41541-021-00361-0","article-title":"Single dose rVSV\u0394G-JUNVGP vaccine protects Guinea pigs against lethal Junin virus challenge","volume":"6","author":"Sorvillo","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B27","doi-asserted-by":"publisher","first-page":"7755","DOI":"10.1038\/s41598-019-44210-6","article-title":"Vesicular stomatitis virus-based vaccine protects mice against Crimean-Congo hemorrhagic fever","volume":"9","author":"Rodriguez","year":"2019","journal-title":"Sci Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e2200065119","DOI":"10.1073\/pnas.2200065119","article-title":"A recombinant VSV-vectored vaccine rapidly protects nonhuman primates against lethal Nipah virus disease","volume":"119","author":"Foster","year":"2022","journal-title":"Proc Natl Acad Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad693","article-title":"Immunogenicity and vaccine shedding after 1 or 2 doses of rVSV\u0394G-ZEBOV-GP Ebola vaccine (ERVEBO\u00ae): results from a phase 2, randomized, placebo-controlled trial in children and adults","volume":"78","author":"Lee","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-021-05035-9","article-title":"Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries","volume":"22","author":"Badio","year":"2021","journal-title":"Trials"},{"key":"B31","doi-asserted-by":"publisher","first-page":"7666","DOI":"10.1038\/s41467-024-51453-z","article-title":"Long-term cellular immunity of vaccines for Zaire Ebola Virus Diseases","volume":"15","author":"Wiedemann","year":"2024","journal-title":"Nat\u00a0Commun"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy565","article-title":"Detectable vesicular stomatitis virus (VSV)\u2013specific humoral and cellular immune responses following VSV\u2013Ebola virus vaccination in humans","volume":"219","author":"Poetsch","year":"2019","journal-title":"J Infect Dis"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.127537","article-title":"Long-term antibody responses to the Ebola virus and the vaccine vector after rVSV-ZEBOV vaccination in DRC","volume":"62","author":"Kahusu","year":"2025","journal-title":"Vaccine"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2432353","article-title":"Evaluation of waning of IgG antibody responses after rVSV\u0394G-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial","volume":"14","author":"Valayer","year":"2025","journal-title":"Emerging Microbes Infections"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/v17030342","article-title":"Durability of immunogenicity and protection of rVSV\u0394 G-ZEBOV-GP vaccine in a nonhuman primate EBOV challenge model","volume":"17","author":"Bixler","year":"2025","journal-title":"Viruses"},{"key":"B36","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/s41541-022-00567-w","article-title":"Sequential use of Ad26-based vaccine regimens in NHP to induce immunity against different disease targets","volume":"7","author":"Khan","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00819-8","article-title":"Case fatality risk among individuals vaccinated with rVSV\u0394G-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo","volume":"24","author":"Coulborn","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw218","article-title":"Efficacy of vesicular stomatitis virus\u2013Ebola virus postexposure treatment in rhesus macaques infected with Ebola virus makona","volume":"214","author":"Marzi","year":"2016","journal-title":"J Infect Dis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1546582","article-title":"Durability of single-dose rVSV-ZEBOV vaccine responses: what do we know","volume":"17","author":"Huttner","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00210-X","article-title":"Urgent considerations for booster vaccination strategies against Ebola virus disease","volume":"24","author":"Adriaensen","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(24)00163-0","article-title":"Safety and immunogenicity of a delayed booster dose of the rVSV\u0394G-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial","volume":"5","author":"Davey","year":"2024","journal-title":"Lancet Microbe"},{"key":"B42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.tim.2018.08.008","article-title":"Can Ebola virus vaccines have universal immune correlates of protection","volume":"27","author":"Meyer","year":"2019","journal-title":"Trends Microbiol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0233-9","article-title":"Antibody-mediated protection against Ebola virus","volume":"19","author":"Saphire","year":"2018","journal-title":"Nat Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrmicro2129","article-title":"Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule","volume":"7","author":"Sullivan","year":"2009","journal-title":"Nat Rev Microbiol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2023.168297","article-title":"DNA vaccines: history, molecular mechanisms and future perspectives","volume":"435","author":"Pagliari","year":"2023","journal-title":"J Mol Biol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00151-9","article-title":"Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India","volume":"399","author":"Khobragade","year":"2022","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41434-020-00204-y","article-title":"Self-amplifying RNA vaccines for infectious diseases","volume":"28","author":"Bloom","year":"2021","journal-title":"Gene Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"7469","DOI":"10.1038\/s41467-024-50376-z","article-title":"Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases","volume":"15","author":"Baden","year":"2024","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e1010078","DOI":"10.1371\/journal.ppat.1010078","article-title":"Current state of Ebola virus vaccines: A snapshot","volume":"17","author":"Woolsey","year":"2021","journal-title":"PloS Pathog"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e19036","article-title":"Brief review on ebola virus disease and one health approach","volume":"9","author":"Hussein","year":"2023","journal-title":"Heliyon"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00416-8","article-title":"The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats","volume":"16","author":"Osterholm","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2471\/BLT.22.289521","article-title":"WHO target product profiles to shape global research and development","volume":"2023","author":"Charnaud","year":"2023","journal-title":"Bull World Health Organ"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix592","article-title":"Modified mRNA-based vaccines elicit robust immune responses and protect Guinea pigs from Ebola virus disease","volume":"217","author":"Meyer","year":"2018","journal-title":"J Infect Dis"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA Vaccines Protect against Zika Virus Infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.789427","article-title":"The critical contribution of pseudouridine to mRNA COVID-19 vaccines","volume":"9","author":"Morais","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e1007564","DOI":"10.1371\/journal.ppat.1007564","article-title":"Complete protection of the BALB\/c and C57BL\/6J mice against Ebola and Marburg virus lethal challenges by pan-filovirus T-cell epigraph vaccine","volume":"15","author":"Rahim","year":"2019","journal-title":"PloS Pathog"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.2.1184","article-title":"Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection1","volume":"175","author":"Warfield","year":"2005","journal-title":"J Immunol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1473698","article-title":"The vesicular stomatitis virus-based Ebola virus vaccine: From concept to clinical trials","volume":"14","author":"Suder","year":"2018","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1086\/520591","article-title":"Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever","volume":"196","author":"Jones","year":"2007","journal-title":"J Infect Dis"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.08.028","article-title":"Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents","volume":"32","author":"Wong","year":"2014","journal-title":"Vaccine"},{"key":"B61","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1371\/journal.ppat.0030002","article-title":"Effective post-exposure treatment of Ebola infection","volume":"3","author":"Feldmann","year":"2007","journal-title":"PloS Pathog"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir348","article-title":"Vesicular stomatitis virus\u2013based Ebola vaccines with improved cross-protective efficacy","volume":"204","author":"Marzi","year":"2011","journal-title":"J Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.vaccine.2009.09.133","article-title":"Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates","volume":"28","author":"Hooper","year":"2009","journal-title":"Vaccine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.smim.2018.07.003","article-title":"Correlates of vaccine-induced protective immunity against Ebola virus disease","volume":"39","author":"Medaglini","year":"2018","journal-title":"Semin Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy352","article-title":"T-cell receptor diversity and the control of T-cell homeostasis mark Ebola virus disease survival in humans","volume":"218","author":"Speranza","year":"2018","journal-title":"J Infect Dis"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2447","article-title":"CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates","volume":"17","author":"Sullivan","year":"2011","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s12985-022-01858-3","article-title":"Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis","volume":"19","author":"Mehrabi Nejad","year":"2022","journal-title":"Virol J"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv215","article-title":"Interferon \u03b1\/\u03b2 Receptor\u2013deficient mice as a model for Ebola virus disease","volume":"212","author":"Brannan","year":"2015","journal-title":"J Infect Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2018.04.027","article-title":"Recently identified mutations in the ebola virus-makona genome do not alter pathogenicity in animal models","volume":"23","author":"Marzi","year":"2018","journal-title":"Cell Rep"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy141","article-title":"The makona variant of Ebola virus is highly lethal to immunocompromised mice and immunocompetent ferrets","volume":"218","author":"Wong","year":"2018","journal-title":"J Infect Dis"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.09.012","article-title":"Immunocompromised Cas9 transgenic mice for rapid in vivo assessment of host factors involved in highly pathogenic virus infection","volume":"23","author":"Collette","year":"2021","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-023-00699-7","article-title":"YF17D-vectored Ebola vaccine candidate protects mice against lethal surrogate Ebola and yellow fever virus challenge","volume":"8","author":"Lemmens","year":"2023","journal-title":"NPJ Vaccines"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.79.22.14189-14196.2005","article-title":"Protective cytotoxic T-cell responses induced by Venezuelan equine encephalitis virus replicons expressing Ebola virus proteins","volume":"79","author":"Olinger","year":"2005","journal-title":"J Virol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.cell.2018.07.033","article-title":"Systematic analysis of monoclonal antibodies against Ebola virus GP defines features that contribute to protection","volume":"174","author":"Saphire","year":"2018","journal-title":"Cell"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/srep20514","article-title":"Discovery of an antibody for pan-Ebolavirus therapy","volume":"6","author":"Furuyama","year":"2016","journal-title":"Sci Rep"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.1016\/j.celrep.2018.08.009","article-title":"Structural basis of pan-Ebolavirus neutralization by an antibody targeting the glycoprotein fusion loop","volume":"24","author":"Murin","year":"2018","journal-title":"Cell Rep"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1600299113","article-title":"Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose","volume":"113","author":"Chahal","year":"2016","journal-title":"Proc Natl Acad Sci"},{"key":"B79","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.immuni.2023.03.005","article-title":"Spheromers reveal robust T cell responses to the Pfizer\/BioNTech vaccine and attenuated peripheral CD8+ T cell responses post SARS-CoV-2 infection","volume":"56","author":"Gao","year":"2023","journal-title":"Immunity"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15892-3","article-title":"Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines","volume":"363","author":"Webby","year":"2004","journal-title":"Lancet"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1129118","article-title":"Construction and immunogenicity of an mRNA vaccine against chikungunya virus","volume":"14","author":"Liu","year":"2023","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.01.059","article-title":"Cellular and humoral immunity to Ebola Zaire glycoprotein and viral vector proteins following immunization with recombinant vesicular stomatitis virus-based Ebola vaccine (rVSV\u0394G-ZEBOV-GP)","volume":"41","author":"Raabe","year":"2023","journal-title":"Vaccine"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2300434","article-title":"Defining parameters that modulate susceptibility and protection to respiratory murine coronavirus MHV1 infection","volume":"212","author":"Silva","year":"2024","journal-title":"J Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1126\/science.274.5284.94","article-title":"Phenotypic analysis of antigen-specific T lymphocytes","volume":"274","author":"Altman","year":"1996","journal-title":"Science"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1329846","article-title":"Identification of mouse CD4+ T cell epitopes in SARS-CoV-2 BA.1 spike and nucleocapsid for use in peptide:MHCII tetramers","volume":"15","author":"Bricio-Moreno","year":"2024","journal-title":"Front Immunol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12864-017-4328-8","article-title":"Mapping HLA-A2,-A3 and-B7 supertype-restricted T-cell epitopes in the ebolavirus proteome","volume":"19","author":"Lim","year":"2018","journal-title":"BMC Genomics"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1806200115","article-title":"Analysis of CD8+ T cell response during the 2013\u20132016 Ebola epidemic in West Africa","volume":"115","author":"Sakabe","year":"2018","journal-title":"Proc Natl Acad Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0455-2","article-title":"Large-scale mapping of the Ebola NP and GP proteins reveals multiple immunoprevalent and conserved CD4 T-cell epitopes","volume":"18","author":"Gallais","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2434","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Zhang","year":"2022","journal-title":"Cell"},{"key":"B91","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41541-025-01076-2","article-title":"Cellular immune breadth of an Omicron-specific, self-amplifying monovalent mRNA vaccine booster for COVID-19","volume":"10","author":"Kumar","year":"2025","journal-title":"NPJ Vaccines"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00026-22","article-title":"Persistence of virus-specific antibody after depletion of memory B cells","volume":"96","author":"Langley","year":"2022","journal-title":"J Virol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.79.21.13231-13238.2005","article-title":"A single-cycle vaccine vector based on vesicular stomatitis virus can induce immune responses comparable to those generated by a replication-competent vector","volume":"79","author":"Publicover","year":"2005","journal-title":"J Virol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e1012393","DOI":"10.1371\/journal.ppat.1012393","article-title":"Evaluation of a novel intramuscular prime\/intranasal boost vaccination strategy against influenza in the pig model","volume":"20","author":"Avanthay","year":"2024","journal-title":"PloS Pathog"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2017.03.045","article-title":"Dose-dependent T-cell dynamics and cytokine cascade following rVSV-ZEBOV immunization","volume":"19","author":"Dahlke","year":"2017","journal-title":"EBioMedicine"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04527-1","article-title":"Germinal centre-driven maturation of B cell response to mRNA vaccination","volume":"604","author":"Kim","year":"2022","journal-title":"Nature"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B98","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s42003-023-04555-1","article-title":"Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals","volume":"6","author":"Connors","year":"2023","journal-title":"Commun Biol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.02.004","article-title":"Enhancement of antigen-specific CD4+ and CD8+ T cell responses using a self-assembled biologic nanolipoprotein particle vaccine","volume":"35","author":"Weilhammer","year":"2017","journal-title":"Vaccine"},{"key":"B100","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1016\/j.immuni.2021.11.001","article-title":"Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses","volume":"54","author":"Alameh","year":"2021","journal-title":"Immunity"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac103","article-title":"Prospective evaluation of coronavirus disease 2019 (COVID-19) vaccine responses across a broad spectrum of immunocompromising conditions: the COVID-19 vaccination in the immunocompromised study (COVICS)","volume":"75","author":"Haidar","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B102","doi-asserted-by":"publisher","first-page":"e206","DOI":"10.1016\/S1473-3099(25)00174-4","article-title":"Sudan Ebola virus disease outbreak in Uganda","volume":"25","author":"Nakkazi","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"B103","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-coV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20171450","article-title":"Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses","volume":"215","author":"Pardi","year":"2018","journal-title":"J Exp Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.cell.2021.12.026","article-title":"SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans","volume":"185","author":"Mudd","year":"2022","journal-title":"Cell"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.2174\/1566523214666140522122633","article-title":"A hantavirus pulmonary syndrome (HPS) DNA vaccine delivered using a spring-powered jet injector elicits a potent neutralizing antibody response in rabbits and nonhuman primates","volume":"14","author":"Kwilas","year":"2014","journal-title":"Curr Gene Ther"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020280","article-title":"Improved DNA vaccine delivery with needle-free injection systems","volume":"11","author":"Ledesma-Feliciano","year":"2023","journal-title":"Vaccines"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1080\/21645515.2015.1039757","article-title":"Codon-optimized filovirus DNA vaccines delivered by intramuscular electroporation protect cynomolgus macaques from lethal Ebola and Marburg virus challenges","volume":"11","author":"Grant-Klein","year":"2015","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.4161\/hv.21873","article-title":"A multiagent filovirus DNA vaccine delivered by intramuscular electroporation completely protects mice from ebola and Marburg virus challenge","volume":"8","author":"Grant-Klein","year":"2012","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9121464","article-title":"mRNA vaccine protects against Zika virus","volume":"9","author":"Medina-Mag\u00fces","year":"2021","journal-title":"Vaccines"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1086\/514292","article-title":"A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever","volume":"179","author":"Bray","year":"1999","journal-title":"J Infect Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2007.05050","article-title":"PepSIRF: a flexible and comprehensive tool for the analysis of data from highly-multiplexed DNA-barcoded peptide assays","author":"Fink","year":"2020"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2207.11509","article-title":"PepSIRF + QIIME 2: software tools for automated, reproducible analysis of highly-multiplexed serology data","author":"Brown","year":"2022","journal-title":"arXiv e-prints"},{"key":"B115","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1089\/vim.2014.0071","article-title":"Cross-protection conferred by filovirus virus-like particles containing trimeric hybrid glycoprotein","volume":"28","author":"Martins","year":"2015","journal-title":"Viral Immunol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1371\/journal.ppat.0020007","article-title":"Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus","volume":"2","author":"Negrete","year":"2006","journal-title":"PloS Pathog"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1414216","article-title":"A recombinant vesicular stomatitis virus Ebola vaccine","volume":"376","author":"Regules","year":"","journal-title":"New Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2016.02.033","article-title":"Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice","volume":"34","author":"Bengtsson","year":"2016","journal-title":"Vaccine"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1682418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T06:37:57Z","timestamp":1767595077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1682418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":118,"alternative-id":["10.3389\/fimmu.2025.1682418"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1682418","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.3389\/fimmu.2025.1682418.s001","asserted-by":"subject"}]},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1682418"}}